NCT02808585View on ClinicalTrials.gov

Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 6, 2017

Study Completion Date

December 6, 2017

Conditions
Heart Failure
Interventions
DRUG

PB1046 Injection

Four weekly subcutaneous injections of PB1046.

DRUG

Placebo Injection

Four weekly subcutaneous injections of placebo.

Trial Locations (5)

32117

Cardiology Associates Research Company, Daytona Beach

33173

Revivial Research, Miami

36207

Pinnacle Research Group, LLC, Anniston

75069

North Dallas Research Associates, McKinney

85381

Phoenix Medical Research, Peoria

Sponsors
All Listed Sponsors
lead

PhaseBio Pharmaceuticals Inc.

INDUSTRY